For convenience, patients often choose to administer the medication on the same day each week
India, 2022) 3,170 (3 mg), 3,520 (7 mg), 3,870 (14 mg) MOUNJARO (Tirzepatide GLP & GIP agonist) Eli Lilly Weekly injection (starting 2.5 mg) Dual agonist breakthrough Not yet approved ZEBOUND (Tirzepatide) Eli Lilly Weekly injection (starting 2.5 mg) Approved for weight loss (US, 2023) ~$1,060/4 injections (88,000) Not available VICTOZA (Liraglutide GLP-1) Novo Nordisk Daily injection: 0.6 mg For Type 2 diabetes (India, 2010) 5,324/month APLEVANT (Dulaglutide GLP-1) Eli Lilly (sold by Lupin in India) Weekly injection: 0.75 mg For Type 2 diabetes (India, 2018) 5,497 per pre-filled pen BYETTA (Exenatide GLP-1) Eli Lilly Twice-daily injection: 0.005 mg Approved for Type 2 diabetes (2007) 6,957 for 60-dose pen Pipeline & Research Therapies GLOO34 (Sun Pharma GLP-1 agonist) Under development in India for obese & overweight patients without diabetes
It should be noted that while promising, its use requires further study and caution to ensure safety and effectiveness
Further research may clarify how these peptides can safely enhance libido and improve sexual health
